Nov. 30 (Bloomberg) — Celgene Corp. can more than triple sales for its best-selling cancer pill Revlimid on new data that may convince doctors to choose the drug as a first option over Johnson & Johnson’s intravenous medicine, Velcade.
Read the original post:
Celgene Cancer Pill to Triple Sales on Threat to J&J (Update1) (Bloomberg)
0 Responses to “Celgene Cancer Pill to Triple Sales on Threat to J&J (Update1) (Bloomberg)”